PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Ketoconazole, sold under the brand name Nizoral, among others, is an antiandrogen, antifungal, and antiglucocorticoid medication used to treat a number of fungal infections. Applied to the skin it is used for fungal skin infections such as tinea, cutaneous candidiasis, pityriasis versicolor, dandruff, and seborrheic dermatitis. Taken by mouth it is a less preferred option and recommended for only severe infections when other agents cannot be used. Other uses include treatment of excessive male-patterned hair growth in women and Cushing's syndrome. Common side effects when applied to the skin include redness. Common side effects when taken by mouth include nausea, headache, and liver problems. Liver problems may result in death or the need for a liver transplantation. Other severe side effects when taken orally include QT prolongation, adrenocortical insufficiency, and anaphylaxis. It is an imidazole and works by hindering the production of ergosterol required for the fungal cell membrane, thereby slowing growth. Ketoconazole was patented in 1977 by Belgian pharmaceutical company Janssen, and came into medical use in 1981. It is available as a generic medication and formulations that are applied to the skin are over the counter in the United Kingdom. In 2023, it was the 140th most commonly prescribed medication in the United States, with more than 3 million prescriptions. The formulation that is taken by mouth was withdrawn in the European Union and in Australia in 2013, and in China in 2015. In addition, its use was restricted in the United States and Canada in 2013.
== Further reading == Arms, Thomas S. Encyclopedia of the Cold War (1994). Brune, Lester H. Chronology of the Cold War, 1917–1992 (Routledge, 2006) 720 pp of brief facts Hanes, Sharon M. and Richard C. Hanes. Cold War Almanac (2 vol 2003), 1460pp of brief facts Parrish, Thomas. The Cold War Encyclopedia (1996) Trahair, Richard C.S. and Robert Miller. Encyclopedia of Cold War Espionage, Spies, and Secret Operations (2012). excerpt Tucker, Spencer C. and Priscilla Mary Roberts, eds. The Encyclopedia of the Cold War: A Political, Social, and Military History (5 Vol., 2007). excerpt van Dijk, Ruud, ed. Encyclopedia of the Cold War (2 vol. 2017) excerpt
Detroit has some of the highest crime rates in the United States, with a rate of 62.18 per 1,000 residents for property crimes and 16.73 per 1,000 for violent crimes (compared to national figures of 32 per 1,000 for property crimes and 5 per 1,000 for violent crime in 2008). Detroit's murder rate was 53 per 100,000 in 2012, ten times that of New York City. A 2012 Forbes report named Detroit the most dangerous city in the United States for the fourth year in a row, citing an FBI survey data that found that the city's metropolitan area had a significant rate of violent crimes: murder and non-negligent manslaughter, rape, robbery, and aggravated assault. According to Detroit officials in 2007, about 65 to 70 percent of homicides in the city were drug-related. The rate of unsolved murders in the city is roughly 70%.
==== B. Aesthetics of the nose – nasal subunits and nasal segments ==== To plan, map, and execute the surgical correction of a nasal defect or deformity, the structure of the external nose is divided into nine aesthetic nasal subunits, and six aesthetic nasal segments, which provide the plastic surgeon with the measures for determining the size, extent, and topographic locale of the nasal defect or deformity.
=== United Fruit Co. and United Brands Company subsidiary === In 1963, the company was sold again, followed by another sale in 1967 to the United Fruit Co. conglomerate. AMK Corporation purchased United Fruit in 1970. Then AMK formed United Brands Company to hold A&W. In 1971, A&W Beverages Inc.—a beverage subsidiary—began supplying bottled A&W products to grocery stores. The bottled products would become available nationally. In 1972, A&W's Canadian division was sold to Unilever. A&W attempted to open restaurants in mainland Japan in the early 1970s, specifically in Fukuoka prefecture and the regions of Kanto and Kansai. The chain's performance on the mainland was sluggish in contrast to Okinawa due to several factors, such as the 1973 oil crisis, prompting the chain to withdraw from the market. A&W's Japanese operations are still handled from Okinawa. There were further fruitless attempts to bring the chain to the mainland: in the 1980s, the Okinawan branch briefly attempted to open restaurants in Kagoshima Prefecture but ended up limiting itself to Okinawa, while in the 2000s a pilot restaurant existed in Tokyo, which was quickly withdrawn. 1978 saw the introduction of a standard menu for use in all restaurants in the USA. In the 1970s, A&W had more stores than McDonald's, with a peak in 1974 of 2,400 units.
Sources: en.wikipedia.org
== Ownership == In 2013, Bain Capital acquired an 80% controlling interest in BPL, previously wholly owned by the UK Government. Three years later, the shareholders decided to sell BPL Holdings to Creat, an investment company based in Beijing that owns part of a plasma fractionator in China. In 2022, Permira and Marcucci entered into an agreement to acquire and merge BPL and Kedrion operations into one venture. As a result, the new company would inherit the shareholders of the companies involved, requiring the support of its co-investors. In this case, FSI, CDP Equity and the other Kedrion shareholders had their shares transferred to the new company. In turn, to complete the agreement, the family group received the support of its co-investors, Ampersand Capital Partners and a wholly owned subsidiary of Abu Dhabi Investment Authority (ADIA). In 2023, the BPL site became known as Kedrion Elstree although its product portfolio continued to be marketed as 'BPL'.
The classic symptoms of diabetes are frequent urination (polyuria), increased thirst (polydipsia), increased hunger (polyphagia), and weight loss. Other symptoms may include blurred vision, itchiness, peripheral neuropathy, recurrent vaginal infections, and fatigue, as well as loss of taste. Many people, however, have no symptoms during the first few years and are diagnosed on routine testing. A small number of people with type 2 diabetes can develop a hyperosmolar hyperglycemic state (a condition of very high blood sugar associated with a decreased level of consciousness and low blood pressure).
Sexual dimorphism exists in some species. Individuals of one sex, usually males develop secondary sexual characteristics that increase their chances of reproductive success. In dolphinfish, males have larger and blunter heads than females. In several minnow species, males develop swollen heads and small bumps known as breeding tubercles during the breeding season. The male green humphead parrotfish has a more well-developed forehead with an "ossified ridge" which plays a role in ritualised headbutting. Dimorphism can also take the form of differences in coloration. Again, it is usually the males that are brightly coloured; in killifishes, rainbowfishes and wrasses the colours are permanent while in species like minnows, sticklebacks, darters and sunfishes, the colour changes with seasons. Such coloration can be very conspicuous to predators, showing that the drive to reproduce can be stronger than that to avoid predation. Males that have been unable to court a female successfully may try to achieve reproductive success in other ways. In sunfish species, like the bluegill, larger, older males known as parental males, which have successfully courted a female, construct nests for the eggs they fertilise. Smaller satellite males mimic female behaviour and coloration to access a nest and fertilise the eggs. Other males, known as sneaker males, lurk nearby and then quickly dash to the nest, fertilising on the run. These males are smaller than satellite males.
== Treatment == Treatment for diabulimia has two goals: stabilizing diabetes by increasing insulin intake and addressing the underlying eating disorder. The standard approach for the treatment of two complex conditions involves a multidisciplinary team of professionals. This team may include an endocrinologist, a psychiatrist, a psychologist, and a dietician. There are several treatment centers in the United States that have programs specifically designed for the co-morbidity of diabetes and eating disorders. There is one non-profit in the U.S. devoted to the education, support, and advocacy for people with diabetes and eating disorders. DBH runs a 24 hour toll-free crisis hotline +1.425.985.364 open 365 days a year.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.